Trump Team Weighs Pulling Funds for Moderna Bird Flu Vaccine
US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said.Most Read from BloombergCuts to Section 8 Housing Assistance Loom Amid HUD UncertaintyThe Trump Administration Takes Aim at Transportation ResearchShelters Await Billions in Federal Money for Homelessness ProvidersNYC’s Congestion Pricing Pulls In $48.
Moderna (NASDAQ: MRNA) became a hot investment during the pandemic as its COVID vaccine made investors bullish on its future.
Moderna shares fell 3% Thursday afternoon, after reports that federal health officials are re-evaluating the company’s $590 million contract to help develop a bird-flu vaccine. Moderna was awarded the ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Moderna (MRNA) reported mixed fourth quarter earnings and full-year 2024 earnings Friday. Moderna's stock was down 5% in premarket trading on the earnings results but rose more than 2% sharply ...
Nvidia reports better-than-expected fourth-quarter earnings as revenue jumps 78% on demand for the company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback